Document is current
Any future updates will be listed below
-
Authors
von Mollendorf, Claire https://orcid.org/0000-0003-0927-1731
Mungun, Tuya
Ulziibayar, Munkhchuluun
Skoko, Paige https://orcid.org/0009-0001-3738-2976
Boelsen, Laura
Nguyen, Cattram https://orcid.org/0000-0002-0599-8645
Batsaikhan, Purevsuren
Suuri, Bujinlkham
Luvsantseren, Dashtseren
Narangerel, Dorj
Tsolmon, Bilegtsaikhan https://orcid.org/0000-0001-5002-6565
Demberelsuren, Sodbayar
Ortika, Belinda D.
Pell, Casey L. https://orcid.org/0000-0003-3883-2163
Wee-Hee, Ashleigh https://orcid.org/0009-0004-3962-4256
Nation, Monica L.
Hinds, Jason
Dunne, Eileen M. https://orcid.org/0000-0001-5542-0780
Mulholland, E. Kim
Satzke, Catherine https://orcid.org/0000-0003-3164-8849
-
Funding
Funding for this research was provided by:
GAVI Alliance (PP61690717A2)
- License Information
-
More Information
Article History
Received: 25 March 2024
Accepted: 24 July 2024
First Online: 3 August 2024
Competing interests
: C.V.M., M.U., C.D.N., P.B., B.S., D.L., C.S., T.M., and E.K.M. are investigators on a Pfizer collaborative research project, exploring the impact of PCV13 introduction on adult pneumonia in Mongolia, outside this work. E.M.D. is currently employed by Pfizer. C.S., E.K.M., and C.D.N. are investigators on a Merck Investigator Studies Program grant funded by MSD outside this work. C.V.M. has participated in expert forums for Pfizer and MSD. C.S. has participated in forums and seminars for Pfizer and MSD. J.H. is co-founder and shareholder of BUGS Bioscience Ltd., a not-for-profit spin-out company of St George’s, University of London. The remaining authors declare no competing interest.
